FDAは先天性心不全の乳児と幼い子供のためのMinimam心臓ステントを承認しました. FDA approves Minima heart stent for infants and young children with congenital heart defects.
FDAは,先天性心不全の治療と,複数の心開閉手術の必要性を減らすために設計された,乳幼児と幼い子供のためのMinimam心臓ステントを承認しました. The FDA has approved the Minima heart stent for infants and young children, designed to treat congenital heart defects and reduce the need for multiple open-heart surgeries. 毎年、約40,000人の米国の赤ちゃんがそのような欠陥を持って生まれています。 Annually, about 40,000 U.S. babies are born with such defects. 伝統的なステントとは異なり,Minimastentは子供の成長と共に成長し,最小侵襲的処置で調整でき,手術の週に比べて通常1日しか入院できない. Unlike traditional stents, the Minima stent grows with the child and can be adjusted through a minimally invasive procedure, allowing for shorter hospital stays—typically just one day compared to a week for surgery.